Naoya Kato graduated from the School of Medicine, Chiba University in Japan in 1986 and started his clinical career as a physician at the First Department of Internal Medicine, School of Medicine, Chiba University, Japan. Until 1989, he was trained as a gastroenterologist and hepatologist. From 1989 to 1992, he was back as a Research Fellow at the First Department of Internal Medicine, School of Medicine, Chiba University. Because hepatitis C virus (HCV) was just discovered in 1989, he simultaneously started his research career about HCV. He received the D.M.S. degree in 1995. His doctoral thesis was “Qualitative and quantitative analyses of serum hepatitis C virus” that was mainly published in the Journal of Clinical Investigation in 1990 and in the journal of Hepatology in 1993. He established qualitative and quantitative methods for HCV RNA and found that interferon treatment is more effective in patients with lower amount of HCV. From 1992, he continued his study about HCV at Virology Division, National Cancer Center Research Institute at Tokyo. From 1993, he entered the Department of Gastroenterology, the University of Tokyo chaired by Professor Masao Omata, his mentor at the School of Medicine, Chiba University, and continued the study about hepatitis viruses and hepatocellular carcinoma (HCC). Until today, his main study themes are functional analyses of HCV protein especially related to inflammation and carcinogenesis, searching for host genetic factors related to disease progression and carcinogenesis in hepatitis C, analysis of replication and sensitivity to new antivirals of hepatitis B virus (HBV) wild and drug resistant mutant types, and mechanism of hepatocarcinogenesis and development of new treatment. Recently he has been transferred to the Institute of Medical Science, University of Tokyo. Now, he is energetically studying the interaction between HCV and host innate immune system and hepatocarcinogenesis by HBV and HCV.
Biography Updated on 7 July 2009